Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CPG 10101 Combination Therapy for the Treatment of Hepatitis C in Non-Responder (Null and Partial Responder) Hepatitis C Virus (HCV) Genotype I Infected Subjects

Study:

CPG 10101 Combination Therapy for the Treatment of Hepatitis C: A Phase II Randomized, Open Label, Multi-Center, Parallel Arm, Controlled Trial of CPG 10101 at Two Different Dose Levels With Pegylated-Interferon-Alpha 2B (PEG-IFN) Plus Ribavirin (RVN) or PEG-IFN Plus RVN Without CPG 10101 in the Treatment of Non-Responder (Null and Partial Responder) HCV Genotype 1 Infected Subjects

Rationale:

n/a

Purpose:

The purpose of this study is to determine the efficacy and tolerability of CPG 10101 at two different dose levels with pegylated-interferon-alpha 2B (PEG-IFN) plus ribavirin (RVN) compared to PEG-IFN and RVN without CPG 10101 in HCV positive subjects who were classified as non-responders to previous adequate PEG-IFN plus RVN therapy.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Hepatitis C Drug: CPG 10101
Drug: Pegylated-interferon-alpha 2b
Drug: Ribavirin		 Phase 2

Verified by Pfizer May, 2008

Sponsored by: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov identifier: NCT00277238

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.